ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1365

Machine Learning-based Berlin Scoring of Magnetic Resonance Images of the Spine in Patients with Ankylosing Spondylitis: Analysis of Data from a Phase 3 Trial with Secukinumab

Amir Jamaludin1, Rhydian Windsor1, Sarim Ather1, Timor Kadir1, Andrew Zisserman1, Juergen Braun2, Lianne Gensler3, Pedro Machado4, Mikkel Østergaard5, Denis Poddubnyy6, Thibaud Coroller7, Brian Porter7, Shephard Mpofu8 and Aimee Readie7, 1University of Oxford, Oxford, United Kingdom, 2Rheumazentrum Ruhrgebiet and Ruhr-University, 44649 Herne, Germany, 3University of California San Francisco, San Francisco, CA, 4University College London, London, United Kingdom, 5Rigshospitalet, University of Copenhagen, Copenhagen, Denmark, 6Charité – Universitätsmedizin Berlin, Berlin, Germany, 7Novartis Pharmaceuticals Corporation, East Hanover, NJ, 8Novartis Pharma AG, Basel, Switzerland

Meeting: ACR Convergence 2020

Keywords: Ankylosing spondylitis (AS), Magnetic resonance imaging (MRI), spondyloarthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 8, 2020

Title: Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster III

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Magnetic resonance imaging (MRI) offers a non-invasive and objective method of early diagnosis and classification, monitoring disease burden and treatment response for patients (pts) with axial spondyloarthritis (axSpA).1 Numerous scoring schemes such as the Ankylosing Spondylitis (AS) Spine MRI Activity (ASspiMRIa) score are available for the quantitative assessment of MRI, but are subject to intra- and inter-rater variability, are labor intensive and costly. Nevertheless, quantification of MRI changes has become an important tool to demonstrate treatment success of biologic drugs in axSpA. In this study, we evaluate the performance of machine learning (ML) based software for the automated Berlin grading of spinal MRI bone marrow edema in pts with AS and compare with expert scoring.

Methods: Fully automated ML software (Figure) was developed to detect and label 23 vertebrae, define vertebral units (VU) as per the Berlin modification of the ASspiMRIa score, and score each VU as either 0 (score of 0) or 1 (score of 1, 2 or 3). The ML algorithm was based on the previously developed SpineNet software.2 Analysis included 108 pts from the secukinumab MEASURE 1 study3, in which imaging was done using T1 and STIR sagittal MRI at baseline and Weeks 16, 52, 104, 156 and 208. Two expert readers (R1 and R2), blinded to treatment and visit, evaluated all images by Berlin-modified ASspiMRIa score. The scores from both readers were binned or categorized into two groups: 0 vs 1, 2, or 3. As a result of multiple pt time points and expert reading sessions, the complete dataset comprised of 10,988 VUs, (8,954 graded by R1, 9,010 graded by R2). Ten-way cross-validation at the VU level was used to train and validate the ML software. The dataset was split into 10 randomly selected subsets, ensuring that each pt appears in only one subset, after which 8 subsets were used for training the ML software, one was used to check for correct training, and one was used for validation. The process was repeated 10 times such that all 10 subsets were used for validation. Area-Under-the-Curve (AUC), accuracy weighted for the frequency of each category, sensitivity and specificity were calculated. Intra- and inter-reader accuracy were also calculated.

Results: Average AUC and accuracy of the software in relation to expert readers’ scores was 0.80 and 72% with a sensitivity of 0.72 and specificity of 0.72. The intra- and inter-reader agreement was 75% (R1), 83% (R2) and 73% respectively. Individual VU scoring of the software vs. readers are presented in the Table as a confusion matrix.

Conclusion: Automated scoring of MR images in AS pts was comparable to that of expert reader-based assessments. ML software has the potential to provide an automated guided-reading approach to scoring MR images, which may enable further clinical insights.

References:

  1. Lukas C, et al. J Rheumatol. 2007;34:862-70.
  2. Jamaludin A, et al. Eur Spine J. 2017;26:1374-83.
  3. Baeten D, et al. N Engl J Med. 2015;373,2534-48.

Processing pipeline of automated Berlin scoring software

Confusion matrix between the software, R1 and R2


Disclosure: A. Jamaludin, None; R. Windsor, None; S. Ather, None; T. Kadir, None; A. Zisserman, None; J. Braun, AbbVie (Abbott), 1, Amgen, 1, 2, 3, BMS, 1, 2, 3, Boehringer Ingelheim, 1, 2, 3, Celgene, 1, 2, 3, Celltrion, 1, 2, 3, Centocor, 1, 2, 3, Chugai, 1, 2, 3, Medac, 1, 2, 3, MSD (Schering-Plough), 1, 2, 3, Mundipharma, 1, 2, 3, Novartis, 1, 2, 3, Pfizer (Wyeth), 1, 2, 3, Roche, 2, Sanofi-Aventis, 1, 2, 3, UCB, 1, 2, 3, Eli Lilly, 1, 2, 3, EBEWE Pharma, 5, 8; L. Gensler, AbbVie, 5, GlaxoSmithKline, 5, Eli Lilly, 5, Novartis, 2, 5, Pfizer, 2, 5, UCB Pharma, 2, 5; P. Machado, Abbvie, 5, Eli Lilly, 5, Novartis, 5, UCB, 5, Pfizer, 2, Centocor, 8, Janssen, 8, MSD, 8; M. Østergaard, AbbVie, 2, 5, 8, Celgene, 2, 5, 8, Hospira, 5, 8, Janssen, 5, 8, Merck, 2, 5, 8, Novartis, 2, 5, 8, Novo Nordisk, 5, Orion, 5, 8, Regeneron, 5, Roche, 5, 8, UCB, 5, 8, Bristol-Myers Squibb, 2, 5, 8, Eli Lilly, 5, 8, Pfizer, 5, 8, Boehringer Ingelheim, 5, 8, Sandoz, 5, 8, Sanofi, 5, 8; D. Poddubnyy, Eli Lilly and Company, 2, 5, 8, MSD, 2, 5, 8, Novartis, 2, 5, 8, Pfizer, 2, 5, 8, BioCad, 5, Gilead, 5, GSK, 5, UCB, 5, 8, BMS, 8; T. Coroller, Novartis, 1, 3; B. Porter, Novartis, 1, 3; S. Mpofu, Novartis, 1, 3; A. Readie, Novartis, 1, 3.

To cite this abstract in AMA style:

Jamaludin A, Windsor R, Ather S, Kadir T, Zisserman A, Braun J, Gensler L, Machado P, Østergaard M, Poddubnyy D, Coroller T, Porter B, Mpofu S, Readie A. Machine Learning-based Berlin Scoring of Magnetic Resonance Images of the Spine in Patients with Ankylosing Spondylitis: Analysis of Data from a Phase 3 Trial with Secukinumab [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/machine-learning-based-berlin-scoring-of-magnetic-resonance-images-of-the-spine-in-patients-with-ankylosing-spondylitis-analysis-of-data-from-a-phase-3-trial-with-secukinumab/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/machine-learning-based-berlin-scoring-of-magnetic-resonance-images-of-the-spine-in-patients-with-ankylosing-spondylitis-analysis-of-data-from-a-phase-3-trial-with-secukinumab/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology